Morison launches local production of three high-demand drugs – Reuters


Marking a milestone in the local pharmaceutical industry, Hemas Group subsidiary Morison Ltd has recently commenced manufacturing of Bisoprolol BP 5mg 250s tablets, Ros-10 (rosuvastatin IP tablets 10mg 30s blister) and ChlorMor (rosuvastatin tablets IP 10mg 30s blister) chlorphenamine BP 4mg 100s blister).

These high-demand medicines are now more affordable and accessible to Sri Lankans, whose supply should not depend on imports.

For the first time in Sri Lanka, Bisoprolol 5mg tablets are now manufactured locally by Morison and supplied to the Medical Supplies Division for use in government hospitals. Used as a treatment for high blood pressure and other cardiovascular diseases, the annual requirement for bisoprolol in the public sector is approximately 40 million tablets, which were imported to date.

By producing the same locally, Morison is able to achieve significant foreign exchange savings for the national economy during these unprecedented times. Plans are underway to make Bisoprolol BP 2.5mg and 5mg available in all major pharmacies as a brand name drug in due course to enable purchase via a valid prescription.

The second new product launched, Ros-10 (Rosuvastatin IP tablets 10mg 30s blister) is used to treat hypercholesterolemia, a risk factor for cardiovascular disease. Morison launched Ros-10 at around half of the current weighted average market price, offering significant savings to Sri Lankans.

The third latest addition to the Morison portfolio, ChlorMor (Chlorphenamine tablets BP 4mg 100s blister) is an oral antihistamine that helps relieve allergy symptoms. This too was launched at a lower price than the prevailing similar products in the market.

“This is indeed a key milestone for Morison as well as for the country’s pharmaceutical industry. We commenced operations of our latest state-of-the-art manufacturing and research facility at Homagama in May this year, which is the largest investment to date in the pharmaceutical manufacturing industry in Sri Lanka. This will be a big boost for the country’s pharmaceutical supply during this crucial hour,” said Morison Limited Managing Director Dinesh Athapaththu.

Being the first and largest factory for manufacturing General Oral Solid Dosages (OSD) and Oral Liquid Dosages (OLD) in compliance with WHO and EU GMP infrastructure and Quality Management Systems in Sri Lanka , Morison’s second manufacturing plant in Homagama has the built-in capacity to produce 5 billion tablets and 2 million liters of liquids per year, which is equivalent to 40% of the national annual general OSD demand in Sri Lanka.

Prior to introducing Ros-10, Bisoprolol and ChlorMor, Morison launched the very first locally manufactured SGLT2 (sodium-glucose-2 cotransporter) molecule, empagliflozin 10mg and 25mg tablets in 2021. An oral drug to treat type 2 diabetes, it was launched at a price advantage of approximately 50% compared to the market.


Comments are closed.